Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Buy the report for SLNO
The free brief above is the whole reading. Each report is the same data as a presentation-ready document, generated for this company at the moment of purchase.
Order SLNO
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
Each company listed discloses SLNO in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SLNO in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Anish Bhatnagar | $640,000 | $0 | $46,883,000 | $3,231,230 | $403,200 | $0 | $3,000 | $51,160,430 |
| CEO and Chairman of the Board | ||||||||
| James Mackaness | 460,000 | 0 | 6,923,200 | 1,195,555 | 193,200 | 0 | 3,000 | 8,774,955 |
| Chief Financial Officer | ||||||||
| Meredith Manning | 415,179 | 0 | 1,947,200 | 5,234,010 | 173,661 | 0 | 13,000 | 7,783,050 |
| Chief Commercial Officer | ||||||||
| Patricia Hirano | 375,000 | 0 | 5,018,600 | 516,997 | 137,813 | 0 | 3,000 | 6,051,410 |
| Senior Vice President, Regulatory Affairs | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Anish Bhatnagar | $51,160,430 | $4,116,434 | — | +47,043,996 |
| James Mackaness | 8,774,955 | 1,211,636 | — | +7,563,319 |
| Meredith Manning | 7,783,050 | — | — | — |
| Patricia Hirano | 6,051,410 | 1,028,973 | — | +5,022,437 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Anish Bhatnagar | Option | 19,688 | 33.6 | — |
| Anish Bhatnagar | Option | 227,520 | 5.25 | — |
| Anish Bhatnagar | Option | 59,896 | 2.41 | — |
| Patricia Hirano | Option | 3,029 | 33.6 | — |
| James Mackaness | Option | 37,000 | 36.7 | — |
| Patricia Hirano | Option | 1,987 | 5.1 | — |
| Anish Bhatnagar | RSU | 425,000 | — | 19,103,750 |
| James Mackaness | RSU | 50,000 | — | 2,247,500 |
| Patricia Hirano | Option | 39,879 | 5.25 | — |
| Anish Bhatnagar | Option | 11,014 | 5.1 | — |
| Patricia Hirano | Option | 10,417 | 2.41 | — |
| James Mackaness | Option | 3,521 | 5.1 | — |
| Patricia Hirano | RSU | 42,500 | — | 1,910,375 |
| Meredith Manning | RSU | 40,000 | — | 1,798,000 |
| Anish Bhatnagar | Option | 100,000 | 36.7 | — |
| James Mackaness | Option | 15,625 | 2.41 | — |
| Meredith Manning | Option | 128,000 | 46.31 | — |
| James Mackaness | Option | 41,202 | 5.25 | — |
| Patricia Hirano | Option | 16,000 | 36.7 | — |
The company embraces a performance-oriented compensation philosophy focused on creating long-term value, heavily weighting variable, at-risk pay through short-term cash incentives and long-term equity awards to align executive interests with stockholder returns and business goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dawn BirIndependent · Nominating and Corporate Governance | $17,942 | $655,980 | — | — | — | $673,922 |
| William G. HarrisIndependent · Audit (Chair) · Compensation | 70,000 | 290,160 | — | — | — | 360,160 |
| Matthew PaulsIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance (Chair) | 64,161 | 290,160 | — | — | — | 354,321 |
| Birgitte VolckIndependent · Audit · Nominating and Corporate Governance | 57,500 | 290,160 | — | — | — | 347,660 |
| Ernest MarioIndependent · Departed during FY | 54,688 | 290,160 | — | — | — | 344,848 |
| Andrew SinclairIndependent · Audit · Compensation (Chair) | 0 | 290,160 | — | — | — | 290,160 |
| Gwen MelincoffIndependent · Not standing for re-election | 23,874 | 0 | — | — | — | 23,874 |
| Anish BhatnagarIndependent · Board Chair | — | — | — | — | — | — |
| Annual cash retainer | $42,500 |
|---|---|
| Annual equity retainer | $6,500 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $288,165 |
| Equity awards (grant-date value) | $2,106,780 |
| All other compensation | $0 |
| Total cost of the board | $2,394,945 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Soleno Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Soleno Therapeutics.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Soleno Therapeutics | 2024 | Anish Bhatnagar | $640,000 | $46,883,000 | $3,231,230 | $403,200 | $51,160,430 |
| 2 | Cogent Biosciences Inc. | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 3 | Viking Therapeutics Inc. | 2025 | Brian Lian | 672,000 | 17,756,817 | 2,468,016 | 373,000 | 21,269,833 |
| 4 | Rhythm Pharmaceuticals Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 5 | CymaBay Therapeutics Inc | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 6 | Mirum Pharmaceuticals Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 7 | Geron Corporation | 2025 | Harout Semerjian | 261,667 | 0 | 9,695,400 | 203,000 | 10,221,755 |
| 8 | Arcus Biosciences Inc. | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 9 | Travere Therapeutics Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 10 | Vir Biotechnology Inc. | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 11 | Vera Therapeutics Inc. | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 12 | Viridian Therapeutics Inc. | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 13 | KalVista Pharmaceuticals Inc. | 2024 | Benjamin Palleiko | 580,441 | 5,486,659 | 302,468 | 0 | 6,772,197 |
| 14 | Pliant Therapeutics Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 15 | REGENXBIO Inc. | 2025 | Curran Simpson | 665,510 | 777,448 | 2,350,302 | 387,327 | 4,200,712 |
| 16 | Amylyx Pharmaceuticals Inc. | 2025 | Justin Klee | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 17 | Alector Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Soleno Therapeutics | not disclosed | not disclosed | not disclosed | Aon plc |
| Alector Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Amylyx Pharmaceuticals Inc. | 106.5% | not disclosed | No | Pearl Meyer |
| Arcus Biosciences Inc. | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Cogent Biosciences Inc. | 135% | not disclosed | No | Compensia |
| CymaBay Therapeutics Inc | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Geron Corporation | 90% | Options 75 · RSU 25 | not disclosed | Aon |
| KalVista Pharmaceuticals Inc. | not disclosed | not disclosed | No | Aon |
| Mirum Pharmaceuticals Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Pliant Therapeutics Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| REGENXBIO Inc. | 97% | Options 75 · RSU 25 | not disclosed | Willis Towers Watson |
| Rhythm Pharmaceuticals Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Travere Therapeutics Inc. | 150% | not disclosed | No | Aon |
| Vera Therapeutics Inc. | 140% | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
| Viking Therapeutics Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Vir Biotechnology Inc. | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
| Viridian Therapeutics Inc. | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Anish Bhatnagar | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “2024 Summary Compensation Table”. As printed: 51,160,430. Filing ↗machine: r2 · c27 · span 288252–288262 |
| 2 | Section 01, James Mackaness | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “2024 Summary Compensation Table”. As printed: 8,774,955. Filing ↗machine: r4 · c27 · span 292522–292531 |
| 3 | Section 01, Meredith Manning | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “2024 Summary Compensation Table”. As printed: 7,783,050. Filing ↗machine: r8 · c27 · span 300993–301002 |
| 4 | Section 01, Patricia Hirano | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “2024 Summary Compensation Table”. As printed: 6,051,410. Filing ↗machine: r6 · c27 · span 296781–296790 |
| 5 | Section 08, Dawn Bir | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 673,922. Filing ↗machine: span 228634–228641 |
| 6 | Section 08, William G. Harris | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 360,160. Filing ↗machine: span 222976–222983 |
| 7 | Section 08, Matthew Pauls | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 354,321. Filing ↗machine: span 227502–227509 |
| 8 | Section 08, Birgitte Volck | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 347,660. Filing ↗machine: span 226390–226397 |
| 9 | Section 08, Ernest Mario | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 344,848. Filing ↗machine: span 221860–221867 |
| 10 | Section 08, Andrew Sinclair | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 290,160. Filing ↗machine: span 223868–223875 |
| 11 | Section 08, Gwen Melincoff | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: 23,874. Filing ↗machine: span 224722–224728 |
| 12 | Section 08, Anish Bhatnagar | DEF 14A | 2025-04-22 | 0001193125-25-089274 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | computed | Cash 288,165 + equity 2,106,780 + all other 0 = 2,394,945, summed across the director compensation table rows.machine: formula: Σ = 2,394,945 |
| 15 | Soleno Therapeutics (subject), Section 10b CEO total | DEF 14A | 2025-04-22 | 0001193125-25-089274 | CEO total compensation as printed in Soleno Therapeutics's own proxy. As printed: 51,160,430. Filing ↗machine: r2 · c27 · span 288252–288262 |
| 16 | Cogent Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173834 | CEO total compensation as printed in Cogent Biosciences Inc.'s own proxy. As printed: 27,762,684. Filing ↗machine: r2 · c39 · span 369353–369363 |
| 17 | Viking Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-137915 | CEO total compensation as printed in Viking Therapeutics Inc.'s own proxy. As printed: 21,269,833. Filing ↗machine: r2 · c18 · span 395920–395930 |
| 18 | Rhythm Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001628280-26-028375 | CEO total compensation as printed in Rhythm Pharmaceuticals Inc.'s own proxy. As printed: 17,544,525. Filing ↗machine: r2 · c42 · span 513064–513074 |
| 19 | CymaBay Therapeutics Inc, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050429 | CEO total compensation as printed in CymaBay Therapeutics Inc's own proxy. As printed: 12,871,506. Filing ↗machine: r1 · c47 · span 613195–613205 |
| 20 | Mirum Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals Inc.'s own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 21 | Geron Corporation, Section 10b CEO total | DEF 14A | 2026-04-07 | 0000886744-26-000024 | CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. Filing ↗machine: t118 · r6 · c23 · span 1062574–1062584 |
| 22 | Arcus Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001724521-26-000025 | CEO total compensation as printed in Arcus Biosciences Inc.'s own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749 |
| 23 | Travere Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics Inc.'s own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 24 | Vir Biotechnology Inc., Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025379 | CEO total compensation as printed in Vir Biotechnology Inc.'s own proxy. As printed: 7,834,045. Filing ↗machine: t71 · r3 · c22 · span 625913–625922 |
| 25 | Vera Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001140361-26-014002 | CEO total compensation as printed in Vera Therapeutics Inc.'s own proxy. As printed: 6,986,410. Filing ↗machine: r2 · c24 · span 581040–581049 |
| 26 | Viridian Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160344 | CEO total compensation as printed in Viridian Therapeutics Inc.'s own proxy. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778 |
| 27 | KalVista Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2025-08-21 | 0001193125-25-185353 | CEO total compensation as printed in KalVista Pharmaceuticals Inc.'s own proxy. As printed: 6,772,197. Filing ↗machine: span 291290–291299 |
| 28 | Pliant Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-22 | 0001746473-26-000076 | CEO total compensation as printed in Pliant Therapeutics Inc.'s own proxy. As printed: 5,462,901. Filing ↗machine: r2 · c48 · span 436933–436942 |
| 29 | REGENXBIO Inc., Section 10b CEO total | DEF 14A | 2026-04-14 | 0001193125-26-155058 | CEO total compensation as printed in REGENXBIO Inc.'s own proxy. As printed: 4,200,712. Filing ↗machine: r2 · c16 · span 436444–436453 |
| 30 | Amylyx Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-171800 | CEO total compensation as printed in Amylyx Pharmaceuticals Inc.'s own proxy. As printed: 2,719,807. Filing ↗machine: r4 · c29 · span 597623–597632 |
| 31 | Alector Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186928 | CEO total compensation as printed in Alector Inc.'s own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674 |
| 32 | Section 10a, Mirum Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001759425-26-000027 | Mirum Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 33 | Section 10a, Viridian Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-26-160344 | Viridian Therapeutics Inc. names Soleno Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 34 | Section 10a, Amylyx Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-171800 | Amylyx Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 35 | Section 10a, CymaBay Therapeutics Inc reciprocity | DEF 14A | — | 0001104659-26-050429 | CymaBay Therapeutics Inc's most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 36 | Section 10a, Cogent Biosciences Inc. reciprocity | DEF 14A | — | 0001193125-26-173834 | Cogent Biosciences Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 37 | Section 10a, Alector Inc. reciprocity | DEF 14A | — | 0001193125-26-186928 | Alector Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 38 | Section 10a, Rhythm Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001628280-26-028375 | Rhythm Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 39 | Section 10a, Vera Therapeutics Inc. reciprocity | DEF 14A | — | 0001140361-26-014002 | Vera Therapeutics Inc. names Soleno Therapeutics in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 40 | Section 10a, Geron Corporation reciprocity | DEF 14A | — | 0000886744-26-000024 | Geron Corporation's most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 41 | Section 10a, Pliant Therapeutics Inc. reciprocity | DEF 14A | — | 0001746473-26-000076 | Pliant Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 42 | Section 10a, Travere Therapeutics Inc. reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 43 | Section 10a, Vir Biotechnology Inc. reciprocity | DEF 14A | — | 0001628280-26-025379 | Vir Biotechnology Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |
| 44 | Section 10a, Viking Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-26-137915 | Viking Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Soleno Therapeutics. Filing ↗ |